Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Share-based Compensation (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Share-based Compensation for 3 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 21.6% to $8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.9 million through Dec 2025, up 11.21% year-over-year, with the annual reading at $35.9 million for FY2025, 11.21% up from the prior year.
  • Share-based Compensation for Q4 2025 was $8.0 million at Nuvation Bio, roughly flat from $8.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $12.0 million in Q2 2025, with the low at $3.7 million in Q4 2023.
  • Average Share-based Compensation over 3 years is $7.3 million, with a median of $7.7 million recorded in 2024.
  • The sharpest move saw Share-based Compensation soared 173.75% in 2024, then fell 21.6% in 2025.
  • Over 3 years, Share-based Compensation stood at $3.7 million in 2023, then skyrocketed by 173.75% to $10.2 million in 2024, then dropped by 21.6% to $8.0 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $8.0 million, $8.0 million, and $12.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.